A Study to Evaluate Rozanolixizumab in Study Participants With Generalized Myasthenia Gravis
Status:
Enrolling by invitation
Trial end date:
2023-08-01
Target enrollment:
Participant gender:
Summary
The purpose of this study is to assess the safety, tolerability and efficacy of additional
6-week treatment cycles with rozanolixizumab in study participants with generalized
myasthenia gravis (gMG).